BioSpace News Archive

OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.

ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2022.

Rocket Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease.

Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced a new social media campaign designed to raise awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Elite Pharmaceuticals, Inc. today reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites.

Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company’s commitment to making genetic testing more accessible and equitable for all patient populations.

Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs.